VANCOUVER, British Columbia, Jan. 28, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming LEERINK Partners 5th Annual Global Healthcare Conference in New York city on Thursday, February 11th 2016 at 1:50 PM Eastern Time.
A live audio webcast and archive of the event will be available at: http://wsw.com/webcast/leerink26/aqxp
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing slated to enter Phase 3 clinical trials in 2016 for the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC); a debilitating, chronic condition that is estimated to affect millions of sufferers. Aquinox has a broad intellectual property portfolio surrounding compounds that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
ir@aqxpharma.com
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
Gogawa@troutgroup.com